Intersect ENT Company Profile (NASDAQ:XENT)

About Intersect ENT (NASDAQ:XENT)

Intersect ENT logoIntersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company's commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: N/A
  • Symbol: NASDAQ:XENT
  • CUSIP: N/A
  • Web: www.intersectent.com
Capitalization:
  • Market Cap: $875.67 million
  • Outstanding Shares: 29,189,000
Average Prices:
  • 50 Day Moving Avg: $30.07
  • 200 Day Moving Avg: $26.55
  • 52 Week Range: $7.65 - $33.25
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -76.92
  • P/E Growth: -2.44
Sales & Book Value:
  • Annual Revenue: $87.16 million
  • Price / Sales: 10.05
  • Book Value: $3.88 per share
  • Price / Book: 7.73
Profitability:
  • EBITDA: ($19,710,000.00)
  • Net Margins: -22.94%
  • Return on Equity: -17.60%
  • Return on Assets: -15.64%
Debt:
  • Current Ratio: 9.81%
  • Quick Ratio: 9.17%
Misc:
  • Average Volume: 265,986 shs.
  • Beta: 0.72
  • Short Ratio: 2.34
 

Frequently Asked Questions for Intersect ENT (NASDAQ:XENT)

What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

How were Intersect ENT's earnings last quarter?

Intersect ENT, Inc. (NASDAQ:XENT) posted its earnings results on Tuesday, August, 1st. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.11. The company earned $24 million during the quarter, compared to the consensus estimate of $22.62 million. Intersect ENT had a negative net margin of 22.94% and a negative return on equity of 17.60%. The firm's quarterly revenue was up 24.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.21) earnings per share. View Intersect ENT's Earnings History.

When will Intersect ENT make its next earnings announcement?

Intersect ENT is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Intersect ENT.

Where is Intersect ENT's stock going? Where will Intersect ENT's stock price be in 2017?

10 equities research analysts have issued 1-year price targets for Intersect ENT's shares. Their predictions range from $14.00 to $40.00. On average, they anticipate Intersect ENT's stock price to reach $27.11 in the next year. View Analyst Ratings for Intersect ENT.

What are analysts saying about Intersect ENT stock?

Here are some recent quotes from research analysts about Intersect ENT stock:

  • 1. According to Zacks Investment Research, "Intersect ENT, Inc. is a commercial drug-device company. The Company's initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California. " (10/5/2017)
  • 2. Northland Securities analysts commented, "We remain bullish on the takeout potential of this story. Key Points As a reminder, RESOLVE would be in an office" setting, hence would not be subject to the facility payment pressures currently being witnessed by PROPEL on the Medicare front. It is our understanding that the company would advocate the use of an unlisted J-code (physician administered drug) immediately after NDA approval." (3/13/2017)

Who are some of Intersect ENT's key competitors?

Who are Intersect ENT's key executives?

Intersect ENT's management team includes the folowing people:

  • Lisa D. Earnhardt, President, Chief Executive Officer, Director
  • Jeryl L. Hilleman, Chief Financial Officer
  • Richard E. Kaufman, Senior Vice President, Chief Operating Officer
  • David A. Lehman, General Counsel
  • Gwen Carscadden, Chief People Officer
  • Kieran T. Gallahue, Lead Director
  • Teresa L. Kline, Director
  • William Anthony Vernon, Director
  • Cynthia L. Lucchese, Independent Director
  • Dana G. Mead Jr., Independent Director

Who owns Intersect ENT stock?

Intersect ENT's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Mutual of America Capital Management LLC (0.31%), Nationwide Fund Advisors (0.19%) and Strs Ohio (0.09%). Company insiders that own Intersect ENT stock include Amy Wolbeck, Frederic H Moll, James Stambaugh, Jeryl L Hilleman, Kieran Gallahue, Lisa D Earnhardt and Richard E Kaufman. View Institutional Ownership Trends for Intersect ENT.

Who sold Intersect ENT stock? Who is selling Intersect ENT stock?

Intersect ENT's stock was sold by a variety of institutional investors in the last quarter, including Mutual of America Capital Management LLC and Strs Ohio. Company insiders that have sold Intersect ENT stock in the last year include Jeryl L Hilleman, Lisa D Earnhardt and Richard E Kaufman. View Insider Buying and Selling for Intersect ENT.

Who bought Intersect ENT stock? Who is buying Intersect ENT stock?

Intersect ENT's stock was acquired by a variety of institutional investors in the last quarter, including Nationwide Fund Advisors. View Insider Buying and Selling for Intersect ENT.

How do I buy Intersect ENT stock?

Shares of Intersect ENT can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intersect ENT's stock price today?

One share of Intersect ENT stock can currently be purchased for approximately $30.00.


MarketBeat Community Rating for Intersect ENT (NASDAQ XENT)
Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  232 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  325
MarketBeat's community ratings are surveys of what our community members think about Intersect ENT and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Intersect ENT (NASDAQ:XENT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $27.11 (9.63% downside)
Consensus Price Target History for Intersect ENT (NASDAQ:XENT)
Price Target History for Intersect ENT (NASDAQ:XENT)
Analysts' Ratings History for Intersect ENT (NASDAQ:XENT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/13/2017Canaccord GenuityBoost Price TargetBuy$32.00 -> $37.00LowView Rating Details
9/11/2017Bank of America CorporationBoost Price TargetBuy$33.00 -> $40.00HighView Rating Details
8/22/2017Piper Jaffray CompaniesReiterated RatingBuy$35.00LowView Rating Details
8/2/2017Deutsche Bank AGSet Price TargetBuy$27.00 -> $31.00HighView Rating Details
8/2/2017Northland SecuritiesReiterated RatingHold$25.00HighView Rating Details
5/10/2017William BlairReiterated RatingOutperformLowView Rating Details
5/3/2017WedbushBoost Price TargetOutperform -> Outperform$25.00 -> $26.00HighView Rating Details
12/6/2016GuggenheimInitiated CoverageBuy$20.00N/AView Rating Details
11/4/2016Leerink SwannReiterated RatingOutperform$21.00 -> $14.00N/AView Rating Details
11/2/2016J P Morgan Chase & CoDowngradeOverweight -> Neutral$25.00 -> $16.00N/AView Rating Details
8/4/2016BTIG ResearchReiterated RatingHold$14.00N/AView Rating Details
3/24/2016Cantor FitzgeraldReiterated RatingBuy$29.00N/AView Rating Details
(Data available from 10/24/2015 forward)

Earnings

Earnings History for Intersect ENT (NASDAQ:XENT)
Earnings by Quarter for Intersect ENT (NASDAQ:XENT)
Earnings History by Quarter for Intersect ENT (NASDAQ XENT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017($0.20)N/AView Earnings Details
8/1/2017Q2 2017($0.19)($0.08)$22.62 million$24.00 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.25)($0.23)$19.39 million$20.47 millionViewListenView Earnings Details
2/28/2017Q416($0.20)($0.17)$23.47 million$24.20 millionViewListenView Earnings Details
11/2/2016Q316($0.27)($0.22)$17.80 million$18.50 millionViewN/AView Earnings Details
8/2/2016Q216($0.26)($0.21)$18.91 million$19.30 millionViewN/AView Earnings Details
5/5/2016Q116($0.29)($0.29)$16.92 million$16.69 millionViewN/AView Earnings Details
2/23/2016Q415($0.25)($0.20)$18.36 million$18.80 millionViewListenView Earnings Details
11/4/2015Q315($0.29)($0.35)$14.80 million$14.20 millionViewN/AView Earnings Details
8/5/2015Q215($0.26)($0.23)$14.74 million$15.20 millionViewN/AView Earnings Details
5/6/2015Q115($0.33)($0.23)$13.00 million$13.37 millionViewN/AView Earnings Details
2/26/2015Q414($0.29)($0.16)$12.20 million$13.40 millionViewN/AView Earnings Details
11/5/2014Q314($0.35)($0.32)$8.20 million$9.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Intersect ENT (NASDAQ:XENT)
2017 EPS Consensus Estimate: ($0.77)
2018 EPS Consensus Estimate: ($0.46)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.26)($0.22)($0.24)
Q2 20173($0.19)($0.19)($0.19)
Q3 20173($0.26)($0.17)($0.21)
Q4 20173($0.17)($0.06)($0.13)
Q1 20182($0.16)($0.08)($0.12)
Q2 20182($0.12)($0.11)($0.12)
Q3 20182($0.14)($0.11)($0.13)
Q4 20182($0.14)($0.06)($0.10)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Intersect ENT (NASDAQ:XENT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Intersect ENT (NASDAQ:XENT)
Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 83.12%
Insider Trades by Quarter for Intersect ENT (NASDAQ:XENT)
Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)
Insider Trades by Quarter for Intersect ENT (NASDAQ:XENT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/16/2017Lisa D EarnhardtInsiderSell20,000$28.37$567,400.00View SEC Filing  
10/4/2017Jeryl L HillemanCFOSell12,833$29.96$384,476.68View SEC Filing  
9/25/2017Richard E KaufmanCOOSell13,639$28.97$395,121.83View SEC Filing  
9/15/2017Lisa D EarnhardtInsiderSell20,000$30.19$603,800.00View SEC Filing  
9/5/2017Jeryl L HillemanCFOSell12,833$31.05$398,464.65View SEC Filing  
8/28/2017Richard E KaufmanCOOSell22,425$30.22$677,683.50View SEC Filing  
8/15/2017Lisa D EarnhardtInsiderSell20,000$30.79$615,800.00View SEC Filing  
8/4/2017Jeryl L HillemanCFOSell12,833$29.00$372,157.00View SEC Filing  
7/25/2017Richard E KaufmanCOOSell12,500$28.25$353,125.00View SEC Filing  
7/17/2017Lisa D EarnhardtInsiderSell20,000$29.03$580,600.00View SEC Filing  
7/10/2017Jeryl L HillemanCFOSell12,835$27.18$348,855.30View SEC Filing  
6/15/2017Lisa D EarnhardtInsiderSell20,000$26.10$522,000.00View SEC Filing  
5/22/2017Richard E KaufmanCOOSell20,000$22.87$457,400.00View SEC Filing  
5/15/2017Lisa D EarnhardtInsiderSell20,000$22.98$459,600.00View SEC Filing  
4/20/2017Richard E KaufmanCOOSell1,250$17.25$21,562.50View SEC Filing  
4/17/2017Lisa D EarnhardtInsiderSell20,000$16.06$321,200.00View SEC Filing  
3/15/2017Lisa D EarnhardtInsiderSell20,000$15.02$300,400.00View SEC Filing  
10/20/2016Richard E KaufmanCOOSell3,603$16.58$59,737.74View SEC Filing  
10/17/2016Lisa D EarnhardtInsiderSell400$18.00$7,200.00View SEC Filing  
9/7/2016Amy WolbeckVPSell28,664$15.83$453,751.12View SEC Filing  
9/6/2016James StambaughVPSell4,000$16.00$64,000.00View SEC Filing  
8/3/2016James StambaughVPSell3,977$17.00$67,609.00View SEC Filing  
7/18/2016James StambaughVPSell5,000$15.33$76,650.00View SEC Filing  
6/13/2016James StambaughVPSell500$14.38$7,190.00View SEC Filing  
5/16/2016Kieran GallahueDirectorBuy8,000$12.64$101,120.00View SEC Filing  
4/27/2016Amy WolbeckVPSell2,000$20.01$40,020.00View SEC Filing  
4/20/2016Richard E KaufmanCOOSell3,603$18.86$67,952.58View SEC Filing  
4/18/2016Lisa D EarnhardtCEOSell28,500$18.69$532,665.00View SEC Filing  
3/21/2016Richard E KaufmanCOOSell3,603$16.51$59,485.53View SEC Filing  
3/15/2016Lisa D EarnhardtCEOSell9,000$18.01$162,090.00View SEC Filing  
3/14/2016Frederic H MollDirectorSell1,299$18.53$24,070.47View SEC Filing  
3/8/2016Frederic H MollDirectorSell601$18.56$11,154.56View SEC Filing  
2/22/2016Richard E KaufmanCOOSell3,603$18.65$67,195.95View SEC Filing  
1/21/2016Richard E. KaufmanCOOSell7,206$17.93$129,203.58View SEC Filing  
1/15/2016Lisa D. EarnhardtCEOSell12,500$19.26$240,750.00View SEC Filing  
12/15/2015Lisa D EarnhardtCEOSell6,820$19.85$135,377.00View SEC Filing  
11/16/2015Lisa D EarnhardtCEOSell6,818$18.00$122,724.00View SEC Filing  
10/15/2015Lisa D EarnhardtCEOSell6,818$18.72$127,632.96View SEC Filing  
9/15/2015Lisa D EarnhardtCEOSell6,818$25.99$177,199.82View SEC Filing  
9/11/2015Frederic H MollDirectorSell10,000$25.21$252,100.00View SEC Filing  
8/17/2015Lisa D EarnhardtCEOSell6,818$28.51$194,381.18View SEC Filing  
7/20/2015James StambaughVPSell12,000$30.52$366,240.00View SEC Filing  
7/15/2015Lisa D EarnhardtCEOSell19,318$29.62$572,199.16View SEC Filing  
6/15/2015Lisa D EarnhardtCEOSell19,318$29.30$566,017.40View SEC Filing  
5/8/2015James StambaughVPSell2,785$23.87$66,477.95View SEC Filing  
4/13/2015Amy WolbeckVPSell16,000$26.25$420,000.00View SEC Filing  
4/1/2015James StambaughVPSell8,343$25.50$212,746.50View SEC Filing  
3/16/2015Lisa D EarnhardtInsiderSell19,318$23.56$455,132.08View SEC Filing  
3/11/2015Amy WolbeckVPSell8,000$23.06$184,480.00View SEC Filing  
3/9/2015James StambaughVPSell8,343$23.02$192,055.86View SEC Filing  
2/17/2015Lisa D EarnhardtInsiderSell19,318$22.69$438,325.42View SEC Filing  
2/12/2015Amy WolbeckVPSell8,000$22.12$176,960.00View SEC Filing  
2/2/2015James StambaughVPSell8,343$20.98$175,036.14View SEC Filing  
1/26/2015Robert H Binney JrVPSell6,300$21.18$133,434.00View SEC Filing  
9/11/2014Cynthia L LuccheseDirectorBuy5,000$17.11$85,550.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Intersect ENT (NASDAQ:XENT)
Latest Headlines for Intersect ENT (NASDAQ:XENT)
Source:
Loading headlines, please wait.

Social

Chart

Intersect ENT (XENT) Chart for Tuesday, October, 24, 2017

This page was last updated on 10/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.